This story originally ran on Oct. 15.

Australian firm Tyrian Diagnostics announced this week that it and Becton Dickinson have ended their collaboration to develop a point-of-care diagnostic for active tuberculosis, as neither firm was able to consistently detect Tyrian's lead protein biomarker in clinical samples at high enough sensitivity and specificity levels.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.